

# Hispanics/Latinos in the Bronx Have Improved Survival in Non-Small Cell Lung Cancer Compared with Non-Hispanic Whites



Madelyn Klugman<sup>1</sup>, Xiaonan Xue<sup>1</sup>, Mindy Ginsberg<sup>1</sup>, Haiying Cheng<sup>2</sup>, Thomas Rohan<sup>1</sup>, H. Dean Hosgood, III<sup>1</sup>  
<sup>1</sup>Albert Einstein College of Medicine, Bronx, NY; <sup>2</sup>Montefiore Medical Center, Bronx, NY



## Introduction

- Hispanics are the fastest growing population in the US, and they paradoxically experience similar or better health outcomes compared to Non-Hispanic Whites (NHWs) despite lower socioeconomic status (SES)
- There is a critical need to further understand survival in Hispanics/Latinos with NSCLC after adjustment for important clinical and demographic variables such as smoking.


## Aims

- Assess the roles of race and ethnicity in NSCLC survival and factors related to NSCLC survival, using a cohort of patients at Montefiore Medical Center

## Methods

- Lung Cancer Clinical Cohort at Montefiore Medical Center (LC3MMC):
  - Subjects ≥ 18 years
  - No prior cancer history
  - Incident primary lung cancer
  - Any histology
  - Stage 1-4
  - Diagnosed 2004-2017 in the Bronx, NY
  - Demographic data from MMC's clinical systems
  - Tumor-related data from MMC/Einstein's Cancer Registry

### Inclusion criteria



- Outcome: all-cause mortality

## Results

### Risk of death in subjects with NSCLC in LC3MMC\*


Variable	N	HR	95% CI	p value
<b>Race and ethnicity</b>				
Non-Hispanic White	634	1.00	Ref	
Hispanic/Latino	452	0.70	0.57–0.86	0.001
Non-Hispanic Black	752	1.00	0.86–1.16	0.95
Non-Hispanic Asian	38	0.58	0.36–0.95	0.03
<b>Sex</b>				
Males	956	1.00	Ref	
Females	920	0.89	0.78–1.01	0.07
<b>Adenocarcinoma</b>				
No	833	1.00	Ref	
Yes	1043	0.86	0.76–0.97	0.02
<b>Surgery</b>				
No	1177	1.00	Ref	
Yes	699	0.55	0.47–0.65	< 0.001
<b>Palliative care</b>				
No	1534	1.00	Ref	
Yes	342	1.19	1.02–1.39	0.03
<b>Smoking status</b>				
Never-smoker	295	1.00	Ref	
Ever-smoker	1581	1.16	0.97–1.38	0.10
<b>Language preference</b>				
English	1641	1.00	Ref	
Not English	235	1.17	0.93–1.48	0.18
<b>Marital status<sup>b</sup></b>				
Not married	1107	1.00	Ref	
Married	769	0.90	0.79–1.03	0.13
<b>Socioeconomic status<sup>c</sup></b>				
	1876	1.00	0.97–1.02	0.72

\*Models adjusted for age and the variables in the table and stratified by stage, chemotherapy, and radiation. Non Hispanic Asians not included in multivariable analysis due to limited sample size

- In subgroup analyses, the association of Hispanic ethnicity with survival was evident in never-smokers, ever-smokers, females, males, younger, and older patients
- Survival benefit not seen in Hispanics with adenocarcinoma

### Risk of death in subjects with NSCLC in LC3MMC, stratified by racial/ethnic group\*

Variable	Hispanic/Latino (n = 452)		Non-Hispanic White (n = 634)		Non-Hispanic Black (n = 752)	
	HR	95% CI	HR	95% CI	HR	95% CI
<b>Sex</b>						
Males	1.00	Ref	1.00	Ref	1.00	Ref
Females	0.83	0.61–1.12	0.90	0.72–1.12	0.88	0.72–1.07
<b>Adenocarcinoma</b>						
No	1.00	Ref	1.00	Ref	1.00	Ref
Yes	0.93	0.69–1.25	0.70	0.57–0.87	0.93	0.77–1.14
<b>Surgery</b>						
No	1.00	Ref	1.00	Ref	1.00	Ref
Yes	0.60	0.43–0.85	0.55	0.42–0.73	0.51	0.40–0.65
<b>Palliative care</b>						
No	1.00	Ref	1.00	Ref	1.00	Ref
Yes	1.06	0.75–1.51	1.48	1.11–1.97	1.06	0.84–1.34
<b>Smoking</b>						
Never-smoker	1.00	Ref	1.00	Ref	1.00	Ref
Ever-smoker	1.56	1.02–2.39	1.04	0.76–1.42	1.19	0.89–1.58
<b>Language preference</b>						
English	1.00	Ref	1.00	Ref	1.00	Ref
Not English	1.31	0.97–1.76	0.76	0.42–1.36	1.80	0.43–7.48
<b>Marital status<sup>c</sup></b>						
Not married	1.00	Ref	1.00	Ref	1.00	Ref
Married	0.79	0.57–1.09	0.98	0.78–1.22	0.86	0.70–1.06
<b>Socioeconomic status<sup>d</sup></b>						
	1.00	0.95–1.05	1.01	0.97–1.06	0.99	0.96–1.03



## Conclusions

- After adjustment for clinical and social factors such as smoking, Hispanics have improved survival compared to NHWs
- Smoking and Spanish language preference are possible risk factors for death in Hispanics
- Future research should explore the role of genetics, environmental exposures, screening with low-dose CT, and targeted therapy receipt on survival